• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.用于治疗非霍奇金淋巴瘤的维布妥昔单抗：一项系统评价。
Crit Rev Oncol Hematol. 2017 Jan;109:42-50. doi: 10.1016/j.critrevonc.2016.11.009. Epub 2016 Nov 21.
2
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).纳武单抗用于成人霍奇金淋巴瘤（使用RobotReviewer软件进行的快速综述）
Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2.
3
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
4
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.对早期预后不良或晚期霍奇金淋巴瘤患者，比较包括强化BEACOPP方案的一线化疗与包括ABVD方案的化疗。
Cochrane Database Syst Rev. 2017 May 25;5(5):CD007941. doi: 10.1002/14651858.CD007941.pub3.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
7
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.未治疗的霍奇金淋巴瘤患者化疗和放疗在第二原发性恶性肿瘤、总生存期和无进展生存期方面的优化：个体参与者数据分析
Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2.
8
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
9
A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma.非霍奇金淋巴瘤放射治疗效果的系统综述。
Acta Oncol. 2003;42(5-6):605-19. doi: 10.1080/02841860310014435.
10
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.

引用本文的文献

1
Primary intestinal T-cell and natural killer-cell lymphomas: Clinicopathologic and prognostic features of 79 cases in South China.原发性肠道T细胞和自然杀伤细胞淋巴瘤：中国南方79例临床病理及预后特征
Am J Clin Pathol. 2025 Jan 28;163(1):121-133. doi: 10.1093/ajcp/aqae102.
2
Brentuximab vedotin therapy followed by autologous peripheral stem cell transplantation as a viable treatment option for an older adult with transformed lymphoma: a case report and literature review.本妥昔单抗治疗后行自体外周干细胞移植作为老年转化型淋巴瘤患者的一种可行治疗选择：病例报告及文献综述
J Int Med Res. 2024 Jun;52(6):3000605241258597. doi: 10.1177/03000605241258597.
3
Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line.建立并鉴定 TK-ALCL1：一种新型 NPM-ALK 阳性间变大细胞淋巴瘤细胞系。
Hum Cell. 2024 Jul;37(4):1215-1225. doi: 10.1007/s13577-024-01077-8. Epub 2024 May 16.
4
Antibody-drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis.尿路上皮癌中的抗体药物偶联物：科学计量学分析与临床试验分析
Front Oncol. 2024 Mar 14;14:1323366. doi: 10.3389/fonc.2024.1323366. eCollection 2024.
5
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma.复发或难治性弥漫性大B细胞淋巴瘤基于免疫治疗的新策略进展
Exp Hematol Oncol. 2023 Aug 14;12(1):72. doi: 10.1186/s40164-023-00432-z.
6
Cyclopropane-Containing Specialized Metabolites from the Marine Cyanobacterium cf. sp.环丙烷含特殊代谢产物的海洋蓝细菌 cf. 种
Molecules. 2023 May 8;28(9):3965. doi: 10.3390/molecules28093965.
7
[Clinicopathological characteristics and prognosis of non-Hodgkin lymphoma in oral and maxillofacial regions: An analysis of 369 cases].口腔颌面部非霍奇金淋巴瘤的临床病理特征及预后：369例分析
Beijing Da Xue Xue Bao Yi Xue Ban. 2023 Feb 18;55(1):13-21. doi: 10.19723/j.issn.1671-167X.2023.01.003.
8
Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.儿童、青少年及青年人群侵袭性非霍奇金淋巴瘤的管理：成人视角与儿童视角对比
Cancers (Basel). 2022 Jun 13;14(12):2912. doi: 10.3390/cancers14122912.
9
Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era.新型免疫治疗弥漫性大 B 细胞淋巴瘤：CAR-T 细胞治疗后时代。
Front Immunol. 2022 Jun 1;13:901365. doi: 10.3389/fimmu.2022.901365. eCollection 2022.
10
NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis.NIPA（间变性淋巴瘤激酶的核相互作用伙伴）对有效介导NPM-ALK的淋巴瘤发生至关重要。
Front Oncol. 2022 May 13;12:875117. doi: 10.3389/fonc.2022.875117. eCollection 2022.

本文引用的文献

1
Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review.大剂量化疗及自体造血细胞移植后维持治疗在侵袭性淋巴瘤中的作用：一项系统评价
Biol Blood Marrow Transplant. 2016 Jul;22(7):1182-1196. doi: 10.1016/j.bbmt.2016.02.007. Epub 2016 Feb 16.
2
Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.将Ki-1抗原（CD30）鉴定为系统性肥大细胞增多症的一种新型治疗靶点。
Blood. 2015 Dec 24;126(26):2832-41. doi: 10.1182/blood-2015-03-637728. Epub 2015 Oct 20.
3
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.在一项复发/难治性弥漫性大 B 细胞淋巴瘤（DLBCL）的 2 期研究中，贝林妥欧单抗显示出了客观应答，且 CD30 表达存在差异。
Blood. 2015 Feb 26;125(9):1394-402. doi: 10.1182/blood-2014-09-598763. Epub 2015 Jan 8.
4
Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.本妥昔单抗治疗 CD30+蕈样肉芽肿和赛泽里综合征。
JAMA Dermatol. 2015 Jan;151(1):73-7. doi: 10.1001/jamadermatol.2014.1629.
5
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.本妥昔单抗用于CD30+外周T细胞淋巴瘤患者一线治疗：一项I期研究结果
J Clin Oncol. 2014 Oct 1;32(28):3137-43. doi: 10.1200/JCO.2013.54.2456. Epub 2014 Aug 18.
6
Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression.尽管CD30表达情况各异，但在两名治疗失败的向表皮性皮肤T细胞淋巴瘤患者中，本妥昔单抗显示出显著疗效。
Br J Dermatol. 2015 Mar;172(3):819-21. doi: 10.1111/bjd.13337. Epub 2015 Jan 18.
7
Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.在一名原发性难治性间变性淋巴瘤激酶阳性间变大细胞淋巴瘤患者中，采用 Brentuximab vedotin 联合顺铂/阿糖胞苷治疗。
Onco Targets Ther. 2014 Jun 20;7:1123-7. doi: 10.2147/OTT.S59795. eCollection 2014.
8
Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.在复发或难治性 CD30 阳性霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤的日本患者中进行 brentuximab vedotin 的 I/II 期研究。
Cancer Sci. 2014 Jul;105(7):840-6. doi: 10.1111/cas.12435. Epub 2014 Jul 1.
9
Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.使用维布妥昔单抗治疗后，难治性、溃疡性原发性皮肤CD30+间变性大细胞淋巴瘤完全缓解。
Acta Derm Venereol. 2015 Feb;95(2):233-4. doi: 10.2340/00015555-1874.
10
Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin.在一名患有移植后淋巴细胞增生性疾病和终末期肾病的患者中，使用单药本妥昔单抗治疗使CD30阳性弥漫性大B细胞淋巴瘤完全缓解。
Leuk Lymphoma. 2015 May;56(5):1552-3. doi: 10.3109/10428194.2014.911865.

用于治疗非霍奇金淋巴瘤的维布妥昔单抗：一项系统评价。

Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

作者信息

Berger Garrett K, McBride Ali, Lawson Stephanie, Royball Kelsey, Yun Seongseok, Gee Kevin, Bin Riaz Irbaz, Saleh Ahlam A, Puvvada Soham, Anwer Faiz

机构信息

College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States.

Departments of Medicine, University of Arizona, Tucson, AZ, 85721, United States.

出版信息

Crit Rev Oncol Hematol. 2017 Jan;109:42-50. doi: 10.1016/j.critrevonc.2016.11.009. Epub 2016 Nov 21.

DOI:10.1016/j.critrevonc.2016.11.009
PMID:28010897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5218629/
Abstract

BACKGROUND

Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a CD30-directed antibody, conjugated to the microtubule-disrupting agent MMAE via a protease cleavable linker. BV is FDA approved for use in relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). There are multiple publications for its utility in other malignancies such as diffuse large B-cell lymphoma (DLBCL), mycosis fungoides (MF), Sézary syndrome (SS), T-cell lymphomas (TCL), primary mediastinal lymphoma (PMBL), and post-transplant lymphoproliferative disorders (PTLD). We believe that BV could potentially provide a strong additional treatment option for patients suffering from NHL.

OBJECTIVE

Perform a systematic review on the use of BV in non-Hodgkin lymphoma (NHL) and other CD30 malignancies in humans.

DATA SOURCES

We searched various databases including PubMed (1946-2015), EMBASE (1947-2015), and Cochrane Central Register of Controlled Trials (1898-2015).

ELIGIBILITY CRITERIA

Inclusion criteria specified all studies and case reports of NHLs in which BV therapy was administered.

INCLUDED STUDIES

A total of 28 articles met these criteria and are summarized in this manuscript.

CONCLUSION

Our findings indicate that BV induces a variety of responses, largely positive in nature and variable between NHL subtypes. With additional, properly powered prospective studies, BV may prove to be a strong candidate in the treatment of various CD30 malignancies.

摘要

背景

本妥昔单抗（BV）是一种抗体药物偶联物（ADC），由一种靶向CD30的抗体组成，通过可被蛋白酶裂解的连接子与破坏微管的药物甲磺酸艾瑞布林（MMAE）偶联。BV已获美国食品药品监督管理局（FDA）批准用于复发的经典型霍奇金淋巴瘤（HL）和复发的系统性间变性大细胞淋巴瘤（sALCL）。关于其在其他恶性肿瘤中的应用有多项报道，如弥漫性大B细胞淋巴瘤（DLBCL）、蕈样肉芽肿（MF）、塞扎里综合征（SS）、T细胞淋巴瘤（TCL）、原发性纵隔淋巴瘤（PMBL）以及移植后淋巴增殖性疾病（PTLD）。我们认为BV可能为非霍奇金淋巴瘤（NHL）患者提供一种强有力的额外治疗选择。

目的

对BV在人类非霍奇金淋巴瘤（NHL）和其他CD30恶性肿瘤中的应用进行系统评价。

数据来源

我们检索了多个数据库，包括PubMed（1946 - 2015年）、EMBASE（1947 - 2015年）和Cochrane对照试验中央注册库（1898 - 2015年）。

纳入标准

纳入标准规定为所有接受BV治疗的NHL研究和病例报告。

纳入研究

共有28篇文章符合这些标准，并在本手稿中进行了总结。

结论

我们的研究结果表明，BV可引发多种反应，本质上大多为阳性，且在NHL各亚型之间存在差异。通过更多设计合理、样本量充足的前瞻性研究，BV可能会被证明是治疗各种CD30恶性肿瘤的有力候选药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9f9/5218629/51c28bb31105/nihms834426f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9f9/5218629/51c28bb31105/nihms834426f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9f9/5218629/51c28bb31105/nihms834426f1.jpg